The renin-angiotensin system as a target to solve the riddle of endocrine pancreas homeostasis
Francielle Graus-Nunes1, Vanessa Souza-Mello1
1Laboratory of Morphometry, Metabolism, and Cardiovascular Diseases, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Brazil.
Abstract:
Local renin-angiotensin system (RAS) in the pancreas is linked to the modulation of glucose-stimulated insulin secretion (GSIS) in beta cells and insulin sensitivity in target tissues, emerging as a promising tool in the prevention and/or treatment of obesity, diabetes, and systemic arterial hypertension. Insulin resistance alters pancreatic islet cell distribution and morphology and hypertrophied islets exhibit upregulated angiotensin II type 1 receptor, which drives oxidative stress, apoptosis, and fibrosis, configuring beta cell dysfunction and diminishing islet lifespan. Pharmacological modulation of RAS has shown beneficial effects in diet-induced obesity model, mainly related to the translational potential that angiotensin receptor blockers and ECA2/ANG (1-7)/MAS receptor axis modulation have when it comes to islet preservation and type 2 diabetes prevention and/or treatment. This review describes the existing evidence for different approaches to blocking RAS elements in the management of insulin resistance and diabetes and focuses on islet remodeling and GSIS in rodents and humans.
Insights
The pancreatic renin-angiotensin system (RAS) influences insulin secretion and sensitivity. Blocking RAS components shows promise for treating obesity, diabetes, and hypertension by preserving pancreatic islet cells.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Physiology
- Cell Biology
Background:
- The local renin-angiotensin system (RAS) in the pancreas plays a crucial role in regulating glucose-stimulated insulin secretion (GSIS) and insulin sensitivity.
- Insulin resistance is associated with pancreatic islet cell alterations, including upregulated angiotensin II type 1 receptor (AT1R) in hypertrophied islets, leading to oxidative stress, apoptosis, and fibrosis.
- These changes contribute to beta-cell dysfunction and reduced islet lifespan, impacting overall metabolic health.
Purpose of the Study:
- To review the evidence for blocking RAS elements in managing insulin resistance and diabetes.
- To focus on the impact of RAS modulation on islet remodeling and GSIS in both rodent and human studies.
- To highlight the therapeutic potential of RAS inhibition for obesity, diabetes, and hypertension.
Main Methods:
- Literature review of existing evidence on pharmacological modulation of the RAS.
- Analysis of studies investigating angiotensin receptor blockers (ARBs) and the ACE2/ANG (1-7)/MAS receptor axis.
- Examination of data from rodent models of diet-induced obesity and studies in human subjects.
Main Results:
- Pharmacological RAS modulation demonstrates beneficial effects in preclinical models of obesity.
- Angiotensin receptor blockers and modulation of the ACE2/ANG (1-7)/MAS receptor axis show potential for islet preservation.
- These interventions are associated with the prevention and treatment of type 2 diabetes.
Conclusions:
- The local pancreatic RAS is a significant factor in beta-cell function and insulin resistance.
- Targeting RAS components offers a promising therapeutic strategy for metabolic disorders.
- Further research into RAS modulation is warranted for effective islet preservation and type 2 diabetes management.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Endocrine Signaling
What is Homeostasis?
pH Homeostasis
Respiratory...
Pancreas
The broad head of the pancreas lies within the loop formed by the duodenum, while its slender body reaches towards the spleen. The tail of the pancreas is short...
What is the Endocrine System?


